Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CY-219 CAR-T in Relapsed/Refractory B-Cell Lymphoma
NCT07539688Phase 1Not yet recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- May 2026
- Primary completion
- Mar 2029
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
01
Overview
Phase 1, open-label, single-arm trial of CY-219 in B cell lymphoma, sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoint: Safety indicators at 6 months. Planned start May 2026; status: not yet recruiting.
02
Drugs
CY-219
03
Conditions
B cell lymphoma
Beyond the preview
Go deeper on NCT07539688.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07539688.